Fri, Sep 19, 2014, 4:22 AM EDT - U.S. Markets open in 5 hrs 8 mins

Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

  • mainecoastlover1 mainecoastlover1 Sep 18, 2013 4:54 PM Flag

    SOMETHING I WONDER ABOUT

    If Geron actually has the "real deal" in Imetelstat now.....and those "in the know" (including some hedge funds) are aware of this.....why hasn't GERN spiked $2, $3, $4 or more?......rather than the 20 - 40 cent daily up-ticks we've seen since Chip's "coy" update?

    It's questions like this (and that darned $2.99 GERN close of a year ago) that keep going 'round in my mind and, sometimes, has me taking a couple Tylenol PMs before turning in at night. (but not very often)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Phase II ? Nothing guaranteed here at all. Trade as appropriate. Have some fun with this.

    • Two possible reasons.

      #1. It is not known for sure that Imetelstat is as you call it the real deal until the data is released. Scarlett's coyness could just be a prep for another secondary.
      #2. The hedge funds and others who as you put it are in the know are controlling an orderly movement upward so as not to get to much attention, and to pick up as many cheap shares as possible.

      Interesting that you are asking for people's opinions now when you usually call them cheese impacted or something for having an opinion or idea.

      Sentiment: Hold

    • My 2 cents......I have been in Geron since 2001. Currently, I have a few thoughts on your question mainecoast.

      Scarlett made the positive sounding statements on the conference call (leaked the news) because they already know they will be doing a secondary as soon as the results are presented in December. Leaking the news now will drive the share price up and set the company up for a nice price on the secondary. A lid is being kept on the price so that MMs can accumulate shares now and sell as the secondary gets closer. There will be a push of the stock much higher so that Geron can get a pretty nice price for their shares when they go to fund the trials. MMs will be selling at these much higher prices also to control the price prior to the secondary. The secondary will be gobbled up by Wall Street, or a large Pharma... and, I think the price is already set. It's just a matter of controlling things until that happens. So, the company absolutely knows the real deal with this drug, and so does Wall Street.

      • 3 Replies to zcrazyhorsez
      • Why would other companies not be interested in a piece of this development? It seems that if you are going to speculate, then let us throw this possibility in the ring. There will not be the hSEC albatross (Personally, I do not think that it should been anything but a pearl.) around the neck of Geron, and the results should be quite positive for MF & ET; thus, maybe we should broaden our possible outcomes and remember in the disclosure statements that "past performance is not necessarily indicative of future results," as some here want to argue. (I must remind you of this: "The initial trial results from 14 patients with ET were presented at the American Society of Hematology (ASH) annual meeting in December 2012. The updated results, which showed robust hematologic and molecular responses in patients treated with imetelstat, included data for an additional six months of treatment and follow-up for the original 14 patients, as well as data from four additional patients enrolled in the trial after the data cut-off for the ASH presentation.")

        Sentiment: Hold

      • plausible

      • I think you are right, zcrazyhorsez. It's the way it usually works. The next 8 weeks should be interesting. GLTA

    • Maine-You are looking for a rational explanation for stock movement. It''s not there. Stocks move in a random walk which has proven many times. There is NO logic involved.

    • is imetelstat the real deal?

      that is the question.

      the interference imetelstat plays between telomerase and cancers with short telomeres (i.e. ET) was noticed sometime ago. it seems scarlett was able to focus their pursuits on blood disorders or the cancers with short telomeres.

      why no one (i.e. investors, big pharma) noticed the effectiveness of grn163l on ET is a mystery.

      one guesses that there is now a synergistic momentum happening based on a real possibility that there could be a cure for cancers with short telomeres in the works.

      this momentum looks to continue through the quarterly report presentation in late october and then the mayo presentation the second week in december.

    • Main...stop thinking like this you will end up totally crazy...but maybe are you a SOFT basher?

      Sentiment: Buy

    • Reason: There is still a very long way to realizing the potential of telomerase inhibitors. Lots of costs, risks and uncertainty. No guarantee that Phase II & III trials are going to prove out, no matter who conducts the trials.

      Sentiment: Buy

 
GERN
2.31-0.03(-1.28%)Sep 18 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT